Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer Therapy

用于评估癌症治疗反应的多模态定量成像

• 批准号: 8188738
• 负责人: ERIC C. FREY
• 金额: $ 67.17万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-19 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8188738
• 关键词: Albumins; Anatomy; Angiogenesis Inhibitors; Animal Model; Biology; Brain Neoplasms; Cellularity; Clinical Trials; Cytotoxic Chemotherapy; Data; Environment; FDA approved; Glycolysis; Goals; Histology; Image; Image Analysis; Imaging Techniques; Immunotherapy; Individual; Knowledge; Lesion; Link; Machine Learning; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of lung; Measures; Metabolic; Methionine; Methods; Metric; Modality; Modeling; Molecular Weight; NIH Program Announcements; Noise; Outcome; PET/CT scan; Pathway interactions; Patients; Permeability; Positron-Emission Tomography; Primary Brain Neoplasms; Principal Investigator; Process; Property; Protocols documentation; Reproducibility; Signal Transduction; Statistical Data Interpretation; Systemic disease; Technetium Tc 99m Pentetate; Therapeutic; Tracer; Tumor Biology; Tumor Volume; Validation; base; bevacizumab; cancer therapy; chemotherapeutic agent; imaging modality; improved; instrumentation; malignant breast neoplasm; radiotracer; response; simulation; single photon emission computed tomography; text searching; tool; treatment response; tumor; tumor growth

DESCRIPTION (provided by applicant): Cancers are heterogeneous in biology among patients, tumors in the same patient, and within tumors. As a result, they respond differently to therapy per patient, per tumor and within tumors. Different radiotracers and imaging modalities provide information about different aspects of biology and the physio-metabolic environments of the cancer. As a result, a single modality or radiotracer may not provide sufficient information to predict or assess response to therapy. We hypothesize that improved prediction and assessment of response can thus be obtained by combining quantitative image-derived parameters obtained from multiple imaging modalities or radiotracers. We propose to develop, optimize, and validate approaches for combining multiple image-derived parameters obtained from quantitative imaging procedures in order to optimally predict and assess treatment response. In particular, we propose to combine quantitative metrics from PET/CT, SPECT/CT, and MRI. We will first individually optimize the protocols, acquisition parameters, and imaging methods in order to get the most accurate and reliable parameters to combine. Optimally combining the parameters from different modalities requires knowledge of the reproducibility (precision) of the individual quantitative imaging parameters. We will thus use literature search, phantom studies, realistic simulations, and repeated patient studies to characterize the accuracy and precision of the individual quantitative imaging methods. We will then develop methods to combine the metrics to predict or assess treatment response per patient, per tumor and intra-tumor. We will apply and evaluate these methods in three clinical trials: dynamic and static FDG and FIT PET/CT to assess lung cancer response to cytotoxic chemotherapy; PET/CT and DCE- and DW-MRI in breast cancer response; and SPECT/CT, PET/CT and DCE- and DW-MRI to predict response of brain tumors to anti-angiogenic therapy. In these trials imaging parameters and their signatures will be linked to histology or survival outcomes to provide validation of the combined imaging parameter metrics.

描述(申请人提供)：癌症在患者之间、同一患者中的肿瘤以及肿瘤内的生物学上是不同的。因此，他们对每个患者、每个肿瘤和肿瘤内的治疗反应不同。不同的放射性示踪剂和成像方式提供了有关癌症生物学和生理代谢环境的不同方面的信息。因此，单一的模式或放射性示踪剂可能不能提供足够的信息来预测或评估治疗反应。我们假设，通过组合从多种成像方式或放射性示踪剂获得的定量图像衍生参数，可以改善对反应的预测和评估。我们建议开发、优化和验证结合从定量成像过程中获得的多个图像衍生参数的方法，以便最佳地预测和评估治疗反应。特别是，我们建议将PET/CT、SPECT/CT和MRI的定量指标结合起来。我们将首先对协议、采集参数和成像方法进行单独优化，以获得最准确和可靠的参数组合。最佳组合来自不同模式的参数需要了解单个定量成像参数的重复性(精确度)。因此，我们将使用文献搜索、模体研究、真实模拟和重复的患者研究来表征个体定量成像方法的准确性和精确度。然后，我们将开发方法来结合这些指标来预测或评估每个患者、每个肿瘤和肿瘤内的治疗反应。我们将在三个临床试验中应用和评估这些方法：动态和静态FDG和FIT PET/CT用于评估肺癌对细胞毒化疗的反应；PET/CT和DCE-和DW-MRI用于乳腺癌的反应；SPECT/CT、PET/CT和DCE-和DW-MRI用于预测脑肿瘤对抗血管生成治疗的反应。在这些试验中，成像参数及其签名将与组织学或生存结果联系起来，以提供组合成像参数度量的验证。